Biweekly oxaliplatin in combination with continuous infusional 5-fluorouracil and leucovorin (Modified FOLFOX-4 regimen) as first-line chemotherapy for elderly patients with advanced gastric cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 31, Issue 3, 2008, Pages 259-263

  Liu, Zhi Fang ^a   Guo, Qi Sen ^a   Zhang, Xi Qin ^a   Yang, Xi Gui ^a   Guan, Fang ^b   Fu, Zheng ^a   Wang, Ming Yu ^a  

^a SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

^b SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

5 fluorouracil; Advanced gastric cancer; Chemotherapy; Elderly; Hypersensitivity; Leucovorin; Oxaliplatin

Indexed keywords

ANTIHISTAMINIC AGENT; ERYTHROPOIETIN; FLUOROURACIL; FOLINIC ACID; GRANISETRON; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 11; OXALIPLATIN; STEROID; THROMBOPOIETIN; ANTINEOPLASTIC AGENT; FOLFOX PROTOCOL; PLATINUM COMPLEX;

ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG FEVER; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FLUSHING; GROUPS BY AGE; HAND FOOT SYNDROME; HUMAN; HYPOTENSION; INFECTION; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRURITUS; PUMP; SIDE EFFECT; STOMACH CANCER; STOMATITIS; TACHYCARDIA; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT RESPONSE; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION; DRUG HYPERSENSITIVITY; FOLLOW UP; HEMATOLOGIC DISEASE; INTRAVENOUS DRUG ADMINISTRATION; MORTALITY; PREMEDICATION; STOMACH TUMOR; SURVIVAL RATE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; DRUG HYPERSENSITIVITY; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; GRANISETRON; HEMATOLOGIC DISEASES; HUMANS; INFUSIONS, INTRAVENOUS; LEUCOVORIN; MALE; ORGANOPLATINUM COMPOUNDS; PERIPHERAL NERVOUS SYSTEM DISEASES; PREMEDICATION; STOMACH NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 44949176223     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31815d43ee     Document Type: Article

References (26)

1. Talarico L, Chen G, Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol. 2004;22:4626-4631.
2. Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999;341:2061-2067.
3. Yee KW, Pater JL, Pho L, et al. Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier? J Clin Oncol. 2003;21: 1618-1623.
4. Catalano V, Labianca R, Beretta GD, et al. Gastric Cancer. Crit Rev Oncol Hematol. 2005;54:209-241.
5. Hill ME, Cunningham D. Medical management of advanced gastric Cancer. Cancer Treat Rev. 1998;24:113-118.
6. Al-Batran SE, Atmaca A, Hegewisch-Becker S, et al. Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric Cancer. J Clin Oncol. 2004;22:658-663.
7. De Vita F, Orditura M, Matano E, et al. A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br J Cancer. 2005;92:1644-1649.
8. Lordick F, Lorenzen S, Stollfuss J, et al. Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric Cancer. Br J Cancer. 2005;93:190-194.
9. Sumpter K, Harper-Wynne C, Cunningham D, et al. Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. Br J Cancer. 2005;92:1976-1983.
10. Cavanna L, Artioli F, Codignola C, et al. Oxaliplatin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with meta-static gastric cancer (MGC). Am J Clin Oncol. 2006;29:371-375.
11. Bleiberg H, de Gramont A. Oxaliplatin plus 5-fluorouracil: clinical experience in patients with advanced colorectal Cancer. Semin Oncol. 1998;25:32-39.
12. Parker SL, Tong T, Bolden S, et al. Cancer statistics, 1997. CA Cancer J Clin. 1997;47:5-27.
13. Yeoh KG. How do we improve outcomes for gastric cancer? J Gastroenterol Hepatol. 2007;22:970-972.
14. Ferlay J, Autier P, Boniol M, et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007;18:581-592.
15. Diaz-Rubio E. New chemotherapeutic advances in pancreatic, colorec-tal, and gastric cancers. Oncologist. 2004;9:282-294.
16. Wöhrer SS, Raderer M, Hejna M. Palliative chemotherapy for advanced gastric Cancer. Ann Oncol. 2004;15:1585-1595.
17. Arnould S, Hennebelle I, Canal P, et al. Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines. Eur J Cancer. 2003;39: 112-119.
18. Marchetti P, Galla DA, Russo FP, et al. Apoptosis induced by oxaliplatin in human colon cancer HCT15 cell line. Anticancer Res. 2004;24:219- 226.
19. Kim DY, Kim JH, Lee SH, et al. Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric Cancer. Ann Oncol. 2003;14:383-387.
20. Santini D, Graziano F, Catalano V, et al. Weekly oxaliplatin, 5-fluorou-racil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of a phase II trial. BMC Cancer. 2006;6:125.
21. Nardi M, Azzarello D, Maisano R, et al. FOLFOX-4 regimen as fist-line chemotherapy in elderly patients with advanced gastric cancer: a safety study. J Chemother. 2007;19:85-89.
22. Ibrahim A, Hirschfeld S, Cohen MH, et al. FDA drug approval summaries: oxaliplatin. Oncologist. 2004;9:8 -12.
23. Park YH, Kim BS, Ryoo BY, et al. A phase II study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric Cancer. Br J Cancer. 2006;94:959-963.
24. Shepherd GM. Hypersensitivity reactions to chemotherapeutic drugs. Clin Rev Allergy Immunol. 2003;24:253-262.
25. Gammon D, Bhargava P, McCormick MJ. Hypersensitivity reactions to oxaliplatin and the application of a desensitization protocol. Oncologist. 2004;9:546-549.
26. Thomas RR, Quinn MG, Schuler B, et al. Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer. 2003;97:2301-2307.